HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine

This publication has 29 references indexed in Scilit:

• Impact of Baseline Covariates on the Immunogenicity of a Quadrivalent (Types 6, 11, 16, and 18) Human Papillomavirus Virus‐Like‐Particle Vaccine
  The Journal of Infectious Diseases, 2007
• High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up
  British Journal of Cancer, 2006
• Clinical Implications of Human Papillomavirus in Head and Neck Cancers
  Journal of Clinical Oncology, 2006
• High‐risk human papillomavirus infection of the genital tract of women with a previous history or current high‐grade vulvar intraepithelial neoplasia
  Journal of Medical Virology, 2006
• Optimization and Validation of a Multiplexed Luminex Assay To Quantify Antibodies to Neutralizing Epitopes on Human Papillomaviruses 6, 11, 16, and 18
  Clinical and Vaccine Immunology, 2005
• Human Papillomavirus Genotype Distribution in Low-Grade Cervical Lesions: Comparison by Geographic Region and with Cervical Cancer
  Cancer Epidemiology, Biomarkers & Prevention, 2005
• A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine
  Vaccine, 2004
• Role of human papillomavirus in penile cancer, penile intraepithelial squamous cell neoplasias and in genital warts
  Medical Microbiology and Immunology, 2003
• Simultaneous Quantitation of Antibodies to Neutralizing Epitopes on Virus-Like Particles for Human Papillomavirus Types 6, 11, 16, and 18 by a Multiplexed Luminex Assay
  Clinical and Vaccine Immunology, 2003
• Latent Papillomavirus and Recurring Genital Warts
  New England Journal of Medicine, 1985